LEXINGTON, Mass., May 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has commenced a proposed follow-on public offering of 3,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be offered by Aldeyra. Aldeyra also expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock in the public offering.
Cowen and Company, LLC and Canaccord Genuity Inc. are acting as joint book-running managers and Janney Montgomery Scott LLC and Laidlaw & Company (UK) Ltd. are acting as co-managers for the offering.
A registration statement relating to the shares to be sold in the offering has been filed with the Securities and Exchange Commission, but has not yet become effective. The shares may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained by sending a request to: Cowen and Company, LLC on behalf of the underwriters, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome and noninfectious anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com
CONTACT: Corporate Contact: Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 781-761-4904 Ext. 205 email@example.com Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009 firstname.lastname@example.orgSource:Aldeyra Therapeutics